Periocular and orbital amyloidosis: A case series study
-
Published:2023-05-15
Issue:1
Volume:9
Page:30-36
-
ISSN:2581-5024
-
Container-title:IP International Journal of Ocular Oncology and Oculoplasty
-
language:
-
Short-container-title:IJOOO
Author:
Kadir Syeed Mehbub Ul1ORCID,
Haider Golam2,
Mitra Mukti Rani,
Maurya Rajendra Prakash,
Parveen Nishat,
Hossain Tanjila,
Rashid Riffat,
Hossain Md. Ismail,
Bhowmik Narayon Chandra,
Sultana Sadia
Affiliation:
1. Sheikh Fazilatunnesa Mujib Eye Hospital & Training Institute, Gopalganj, Bangladesh, India
2. h
Abstract
To present the demographic and clinical profile and management strategies of patients with periocular and orbital amyloidosis. This study retrospectively reviewed the clinical records of twelve patients with periocular and orbital amyloidosis between January 2011 and February 2019 in Bangladesh. Clinical evaluation and Imaging studies were helpful to diagnosis the patients, but surgical biopsy followed by histopathological study was done to confirm the diagnosis. All cases were investigated to rule out systemic amyloidosis with limited facility and no systemic involvement was found. Informed written consent for surgical procedure and Clinical photographs were taken for all patients for documentation and clinical research. The study included thirteen patients including nine male (69.2%) and four female (30.8%) patients. Among the patients, seven (53.8%) were unilateral and six (46.2%) were bilateral. Clinical signs and symptoms were visible or palpable periocular mass or tissue infiltration in all 13 (100%) cases, mechanical ptosis was observed in 6 (46.2%) cases, and proptosis or globe displacement was found in 4 (30.8%). Age ranges from 25 years to 65 years. The Mean age ± SD was 48.23 ± 10.64 years. Treatment modalities were mainly open surgical biopsy either excision (53.8%) or debulking (46.2%). Periocular and orbital amyloidosis may present with a wide spectrum of clinical findings depending on the location of the disease. The goal of treatment is to preserve function and to prevent sight-threatening complications.
Publisher
IP Innovative Publication Pvt Ltd
Subject
Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology
Reference27 articles.
1. Hrisomalos F, Pattar GR, Phelps PO, MT Yen , MM Marcet , CN Burkat, Ocular Amyloidosis. Eye Wiki..
2. Amyloid Fibril Protein Nomenclature - 2002
3. Ocular adnexal and orbital amyloidosis: a case series and literature review
4. Rootman J, .Degenerations and depositions. Diseases of the Orbit: A Multidisciplinary Approach.555-64
5. Nomenclature of amyloid and amyloidosis. WHO-IUIS Nomenclature Sub-Committee.Bull World Health Organ 1993;71(1):105-12